Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Fineline Cube Aug 18, 2026
Company Deals

Ledeinno Medical Valley Closes Over 200 Million RMB in Series B+ and B++ Rounds – Shining Capital Leads Backing for Wireless SCS Neuromodulation Platform

Fineline Cube Aug 18, 2026
Company Deals

Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor – Capital Earmarked for OpusOne pVAD Clinical Trials

Fineline Cube Aug 18, 2026
Policy / Regulatory

FDA Issues Discussion Paper on GenAI‑Enabled Medical Devices – Seeks Feedback on Risk Framework, Premarket Evaluation and Postmarket Monitoring by October 19

Fineline Cube Aug 19, 2026
Company Drug

Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 – Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China

Fineline Cube Aug 19, 2026
Company Drug

Lepu Medical’s siRNA Drug MWN117 Wins NMPA Clinical Trial Approval for Overweight and Obesity – INHBE‑Targeting Therapy Shows Synergy Potential with GLP‑1 Agonists

Fineline Cube Aug 19, 2026
Company Drug

Pfizer Halts Development of Sisunatovir, an RSV Antiviral, After Phase II/III Trials

Fineline Cube Oct 9, 2024

U.S. pharmaceutical giant Pfizer (NYSE: PFE) has decided to discontinue the development of sisunatovir, an...

Company Drug

Biogen’s China Unit Gets Conditional NMPA Nod for Qalsody (Tofersen) in ALS Treatment

Fineline Cube Oct 9, 2024

Biogen (NASDAQ: BIIB)’s Chinese subsidiary has announced that it has received conditional approval from the...

Company Drug

Joincare Pharmaceutical Secures NMPA Approval for Triptorelin Microspheres to Treat Endometriosis

Fineline Cube Oct 9, 2024

China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced that it has received...

Company Drug

CSPC Pharmaceutical Secures NMPA Approval for Omalizumab Biosimilar

Fineline Cube Oct 9, 2024

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received marketing approval...

Company Deals

Ningbo Menovo Pharmaceutical Partners with Nanjing Huawe Medicine for High-End Product Development

Fineline Cube Oct 9, 2024

Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538) has entered into a strategic partnership with Nanjing...

Company Drug

CSPC Pharmaceutical’s ADC CPO301 Earns Second Fast-Track Designation in the US for NSCLC Treatment

Fineline Cube Oct 9, 2024

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its best-in-class antibody drug conjugate...

Company Deals Drug

Bio-Thera Solutions Ltd Strikes Licensing Deal with Gedeon Richter for BAT1706 Biosimilar

Fineline Cube Oct 9, 2024

Guangzhou-based Bio-Thera Solutions Ltd has announced a licensing agreement with Hungary’s Gedeon Richter Plc for...

Company Drug

Jiangsu Aidea Pharmaceutical Secures NMPA Approval for Expanded Indication of Fubangde in HIV Treatment

Fineline Cube Oct 9, 2024

China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced that the National Medical Products...

Company Drug

Ascentage Pharma Receives Approval for Two Phase III Trials of APG-2449 in NSCLC

Fineline Cube Oct 9, 2024

China-based biopharmaceutical company Ascentage Pharma (HKG: 6855) has announced that it has received approval from...

Company Medical Device

MicroPort Endovascular MedTech’s Fiber Wool Plug Spring Coil Gains NMPA Marketing Approval

Fineline Cube Oct 9, 2024

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) has received marketing approval from the National...

Policy / Regulatory

NMPA Expands Generic Quality Consistency Evaluation with 83rd Batch of Reference Drugs

Fineline Cube Oct 9, 2024

The National Medical Products Administration (NMPA) in China has announced the release of the 83rd...

Company Deals

Kailera Therapeutics Emerges with USD 400 Million in Series A Funding for Anti-Obesity Pipeline

Fineline Cube Oct 8, 2024

Kailera Therapeutics, a newly launched US-based biotechnology company, secured USD 400 million in Series A...

Company Deals

AstraZeneca Strikes Exclusive Licensing Deal with CSPC Pharma for Oral Lp(a) Disruptor

Fineline Cube Oct 8, 2024

UK pharmaceutical giant AstraZeneca (NASDAQ: AZN, LON: AZN) has announced the signing of an exclusive...

Company Deals

Innovent Biologics and ASK Pharma Forge Strategic Partnership for Limertinib in Lung Cancer Treatment

Fineline Cube Oct 8, 2024

China-based Innovent Biologics Inc. (HKG: 1801) and Jiangsu Aosaikang Pharmaceutical Co., Ltd (ASK Pharma, SHE:...

Company Deals

MediLink Therapeutics Partners with Amgen for Clinical Trial in Small Cell Lung Cancer

Fineline Cube Oct 8, 2024

Suzhou-based biotech MediLink Therapeutics (Suzhou) Co., Ltd has announced a partnership with US pharmaceutical giant...

Company

Cassava Sciences to Pay Over USD 40 Million to Settle SEC Charges Over Alzheimer’s Drug Claims

Fineline Cube Oct 8, 2024

The US Securities and Exchange Commission (SEC) has announced that US-based biotech firm Cassava Sciences...

Company Deals

Wuhan YZY Biopharma Grants Rights to CD3/EpCAM Antibody M701 to Chi Ta TianQing Pharma in China

Fineline Cube Oct 8, 2024

Wuhan YZY Biopharma Co., Ltd (HKG: 2496) has announced that it has granted Chi Ta...

Company Deals

Regor Therapeutics Strikes Deal with Genentech for CDK Inhibitors, Fetching USD 850 Million Upfront

Fineline Cube Oct 8, 2024

Regor Therapeutics Group, a US-based biotech with significant ties to China, has entered into a...

Company Drug

China’s CDE Announces “Care Plan” to Include Pfizer’s Marstaximab for Rare Disease Drug Development

Fineline Cube Oct 8, 2024

The National Health Commission (NHC) of China, through its Center for Drug Evaluation (CDE), has...

Company Deals

Genor Biopharma to Acquire EOC Pharma Group in a Merger Deal, Eyeing Commercialization Synergies

Fineline Cube Oct 8, 2024

Genor Biopharma Holdings Limited (HKG: 6998) has announced a definitive merger agreement with EOC Pharma...

Posts pagination

1 … 332 333 334 … 710

Recent updates

  • Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 – Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China
  • Lepu Medical’s siRNA Drug MWN117 Wins NMPA Clinical Trial Approval for Overweight and Obesity – INHBE‑Targeting Therapy Shows Synergy Potential with GLP‑1 Agonists
  • FDA Issues Discussion Paper on GenAI‑Enabled Medical Devices – Seeks Feedback on Risk Framework, Premarket Evaluation and Postmarket Monitoring by October 19
  • Johnson & Johnson Wins U.S. 510(k) Clearance for MONARCH QUEST 3 Software Update – Advancing Robotic Bronchoscopy Navigation and Targeting
  • Trump Picks White House Policy Advisor Heidi Overton to Lead FDA – Replacing Acting Commissioner Kyle Diamantas After Makary’s Resignation
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 – Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China

Company Drug

Lepu Medical’s siRNA Drug MWN117 Wins NMPA Clinical Trial Approval for Overweight and Obesity – INHBE‑Targeting Therapy Shows Synergy Potential with GLP‑1 Agonists

Policy / Regulatory

FDA Issues Discussion Paper on GenAI‑Enabled Medical Devices – Seeks Feedback on Risk Framework, Premarket Evaluation and Postmarket Monitoring by October 19

Company Medical Device

Johnson & Johnson Wins U.S. 510(k) Clearance for MONARCH QUEST 3 Software Update – Advancing Robotic Bronchoscopy Navigation and Targeting

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.